Loading...
Loading...
MTEM| Name | Value |
|---|---|
| Revenues | 33.6M |
| Cost of Revenue | 19.0M |
| Gross Profit | 14.6M |
| Operating Expense | 21.8M |
| Operating I/L | 11.8M |
| Other Income/Expense | -0.9M |
| Interest Income | 0.5M |
| Pretax | 10.8M |
| Income Tax Expense | 2.3M |
| Net Income/Loss | 8.5M |
Molecular Templates, Inc. is a clinical stage biopharmaceutical company specializing in the development of biologic therapeutics for cancer and other serious diseases. The company's primary focus is on its proprietary biologic engineered toxin body (ETB) drug platform, which is utilized to develop a pipeline of therapies. This includes candidates such as MT-5111, MT-0169, and MT-6402, currently in Phase I clinical trials for various cancer treatments. Additionally, Molecular Templates, Inc. has collaborations with Bristol Myers Squibb to discover and develop novel products containing ETBs directed at multiple targets.
